Welcome to our dedicated page for Establishment Labs Hldgs SEC filings (Ticker: ESTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Establishment Labs Holdings Inc. filings document regulatory disclosures for a British Virgin Islands medical technology issuer listed on Nasdaq. Its Form 8-K reports cover operating results and financial condition, preliminary financial information, Regulation FD presentation materials, credit-agreement amendments, senior secured term-loan obligations, and other material definitive agreements.
The company’s proxy materials disclose board matters, executive compensation, equity awards, shareholder voting items, and governance practices. Together, the filings describe the Motiva-focused breast aesthetics and reconstruction business, capital structure, debt arrangements, forward-looking-statement disclosures, and recurring corporate reporting obligations.
ESTABLISHMENT LABS HOLDINGS INC. director Leslie Gillin received an equity grant of common shares as part of regular board compensation. She acquired 297 common shares on the transaction date instead of a quarterly cash retainer, with the share amount based on the $56.78 closing price.
The shares were issued under the company’s 2018 Equity Incentive Plan and increase her direct holdings to 16,044 common shares. This is a routine, compensation-related award rather than an open-market purchase or sale.
Slotkin Bryan reported acquisition or exercise transactions in this Form 4 filing.
Establishment Labs Holdings Inc. director Bryan Slotkin received an automatic grant of 286 common shares valued at $56.78 per share. These shares were taken in lieu of his quarterly cash retainer under the company’s Outside Director Compensation Policy and issued from the 2018 Equity Incentive Plan.
Following this award, Slotkin directly holds 30,256 common shares. This is a routine, compensation-related equity grant rather than an open‑market share purchase.
LEWIN NICHOLAS SHERIDAN reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Nicholas Sheridan Lewin received a grant of 440 common shares, elected in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy. The shares were issued under the 2018 Equity Incentive Plan at a value based on the closing price of $56.78 per share.
Following this compensation award, Lewin directly holds 1,077,315 common shares. An additional 19,090 common shares are held indirectly through his spouse, reflecting associated family holdings rather than an open-market trade.
SCHUTTER EDWARD J reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Edward J. Schutter received 330 common shares on March 31, 2026 as a share-based retainer. The shares were issued under the company’s 2018 Equity Incentive Plan instead of a quarterly cash retainer, based on the closing share price for the quarter’s last trading day.
After this grant, Schutter directly holds 138,602 common shares, so the award represents a small, routine addition to his existing stake rather than an open-market purchase or sale.
Custin Ann reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Custin Ann reported receiving a grant of 363 common shares. The shares were awarded in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy, based on a closing price of $56.78 per share.
After this equity award issued pursuant to the 2018 Equity Incentive Plan, Custin Ann directly holds a total of 21,732 common shares.
Establishment Labs Holdings Inc. director Juan Jose Chacón Quirós reported an indirect open-market sale of 3,575 common shares at a weighted average price of $60.075 per share. The shares were sold by Sariel Group Ltd. under a pre-arranged Rule 10b5-1 trading plan.
After the sale, indirect holdings reported for Sariel Group Ltd. totaled 1,220,004 common shares, and Chacón Quirós also reported 45,193 common shares held directly. He disclaims beneficial ownership of shares held by Sariel Group Ltd. except to the extent of his pecuniary interest.
ESTABLISHMENT LABS HOLDINGS INC. director Juan Jose Chacon Quiros reported a mix of entity restructuring and open-market sales of Common Shares. A total of 179,240 shares moved from his direct holdings to Sariel Group Ltd. in an exempt transfer, leaving him with 45,193 shares held directly.
Through Sariel Group Ltd., an entity in which he is a shareholder with voting and dispositive power, 33,925 shares were sold in open-market transactions on March 23, 2026 at prices generally between $60.00 and $63.01 per share under a Rule 10b5-1 trading plan. Following these transactions, 1,225,292 shares are reported as held indirectly via Sariel Group Ltd.
ESTABLISHMENT LABS HOLDINGS INC. Chief Financial Officer Cassandra Harris received new equity awards as part of her compensation. She was granted stock options for 12,877 common shares at an exercise price of $74.60 per share and a separate grant of 7,372 common shares.
Both awards vest over four years. One-fourth of the stock units and one-fourth of the option shares will vest on March 9, 2027, with additional one-fourth increments vesting on each one-year anniversary thereafter, as long as she continues as a service provider. Following these awards, she holds 12,877 options and 7,372 common shares directly.
ESTABLISHMENT LABS HOLDINGS INC. executive Cassandra Harris, the company’s Chief Financial Officer, has filed an initial Form 3 insider ownership report. This filing lists her as an officer but does not report any insider transactions or share movements, serving as a baseline disclosure of her status.